ResMed’s first quarter saw the company deliver revenue and earnings above Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s performance to strong growth in its masks and accessories segment, as well as the ongoing rollout of the AirSense 11 platform in new markets like Latin America and China. CEO Michael J. Farrell highlighted operational improvements in supply chain management and logistics, which contributed to margin expansion, and noted the impact of digital and educational initiatives in broadening sleep apnea awareness and diagnosis. The quarter also included the announced retirement of long-serving CFO Brett A. Sandercock, with Aaron Blumer set to assume the role.

Is now the time to buy RMD? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From ResMed’s Q1 Earnings Call

• David L Bailey (Morgan Stanley) asked about recent trends in component and freight costs. CEO Michael J. Farrell and outgoing CFO Brett A. Sandercock explained that while supply chain efficiencies remain, cost inflation on components is becoming more challenging, but productivity initiatives should offset these pressures.
• Jarden (Analyst) inquired about Noctrix Health’s growth and margin profile, and its impact on costs. Farrell confirmed Noctrix’s higher growth and gross margin, but noted ongoing investment in R&D and SG&A will be required, with Sandercock projecting modest short-term EPS dilution.
• Barrenjoey (Analyst) asked about the drivers of Europe/Asia mask growth. Farrell cited strong execution in Western Europe contracts and omnichannel strategies in Asia-Pacific, pointing to premium mask adoption and share gains as main drivers.
• UBS (Analyst) questioned possible disruption from changing U.S. payer models like Synapse. Farrell downplayed the risk, arguing home care utilization management has limited impact on ResMed’s low-acuity, high-value therapy, and that payer/provider partnerships mitigate concerns.
• MST (Analyst) pressed on whether higher mask prices are sustainable for HMEs. Farrell replied that profitability varies by payer and geography, but for most, increased adherence offsets higher costs, and ResMed works to ensure viable economics across major markets.

Catalysts in Upcoming Quarters

In the coming quarters, the StockStory team will monitor (1) the pace of adoption and integration for Noctrix Health’s NIDRA device, (2) further expansion and real-world uptake of new fabric-based masks and AirSense 11 in recently entered markets, and (3) the impact of GLP-1 therapy awareness on overall patient funnel growth. Execution on maintaining supply chain efficiency and profitability amid rising input costs will remain key signposts for progress.

ResMed currently trades at $210.15, down from $213.81 just before the earnings. In the wake of this quarter, is it a buy or sell? Find out in our full research report (it’s free).

Our Favorite Stocks Right Now

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.